This study is to evaluate the safety and tolerability of pan-KRAS inhibitor JAB-23E73 in adult participants with advanced solid tumors
Written informed consent.
Participant must be ≥18 years of age at the time of signing the Informed Consent Form (ICF).
Histologically or cytologically confirmed locally advanced or metastatic solid tumors that are not suitable for curative interventions.
Patients must have KRAS alterations.
Inability to swallow oral medications, or presence of gastrointestinal dysfunction or gastrointestinal disorders that may significantly alter the absorption of the study drug.
Patients who have previously been treated with KRAS G12C inhibitors, KRAS G12D inhibitors, or pan/multi-KRAS inhibitors.
Known serious allergy to JAB-23E73 or excipient.
Patients with primary central nervous system tumors.